文献速递造血干细胞移植与细胞治疗白血病

塞替派、白消安和氟达拉滨与白消安和环磷酰胺作为匹配同胞及无关供者异基因干细胞移植治疗急性髓系白血病的预处理方案比较

Thiotepa, busulfan and fludarabine compared to busulfan and cyclophosphamide as conditioning regimen for allogeneic stem cell transplant from matched siblings and unrelated donors for acute myeloid leukemia.
PubMed 文献 · Am J Hematol · 2018-08-15

该回顾性研究比较了2523例18-50岁缓解期急性髓系白血病患者接受匹配同胞或无关供者移植时,采用TBF与BuCy预处理方案的结局。1:3配对分析显示TBF组复发风险显著低于BuCy组(HR 0.6,P=0.02),非复发死亡无差异,无白血病生存和总生存无显著差异。TBF组III-IV级急性移植物抗宿主病风险有升高趋势(HR 1.8,P=0.06),慢性移植物抗宿主病风险更低(HR 0.7,P=0.04)。

要点

  • TBF较BuCy显著降低复发风险(HR 0.6,P=0.02),非复发死亡无差异。
  • 两组无白血病生存和总生存无显著差异。
  • 首次缓解期患者中TBF复发优势更明显(HR 0.4,P=0.02),无白血病生存有更好趋势(HR 0.7,P=0.10)。

核心结论

  • TBF是一种有效的清髓性预处理方案,与BuCy相比提供显著更低的复发风险和相似的生存。
  • 首次缓解期患者似乎从该方案中获益最大,该亚组中观察到无白血病生存有更好趋势。

研究设计与样本

  • 回顾性比较2523例年龄18-50岁、缓解期急性髓系白血病患者,接受匹配同胞或无关供者异基因干细胞移植,预处理为TBF或BuCy。
  • 进行1:3配对分析:146例接受TBF的患者与438例接受BuCy的患者进行比较。

主要发现

  • TBF组复发风险显著低于BuCy组(HR 0.6,P=0.02),非复发死亡无差异。
  • 两组无白血病生存和总生存无显著差异。
  • TBF与III-IV级急性移植物抗宿主病风险升高趋势相关(HR 1.8,P=0.06),慢性移植物抗宿主病更差(HR 0.7,P=0.04)。
  • 首次缓解期患者中,TBF的复发优势更明显(HR 0.4,P=0.02),无白血病生存有更好趋势(HR 0.7,P=0.10),总生存无差异。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Busulfan plus cyclophosphamide (BuCy) is the traditional conditioning regimen for allogeneic stem cell transplant (allo-SCT) for young, fit patients with acute myeloid leukemia (AML). The thiotepa-busulfan-fludarabine (TBF) protocol has recently demonstrated promising outcome in cord blood and haploidentical SCT; however, there is limited evidence about this regimen in transplant from matched siblings (MSD) and unrelated donors (UD). We retrospectively compared outcomes of 2523 patients aged 18-50 with AML in remission, undergoing transplant from MSD or UD prepared with either TBF or BuCy conditioning. A 1:3 pair-matched analysis was performed: 146 patients receiving TBF were compared with 438 patients receiving BuCy. Relapse risk was significantly lower in the TBF when compared with BuCy group (HR 0.6, P = .02), while NRM did not differ. No significant difference was observed in LFS and OS between the two regimens. TBF was associated with a trend towards higher risk of grades III-IV aGVHD (HR 1.8, P = .06) and inferior cGVHD (HR 0.7, P = .04) when compared with BuCy. In patients undergoing transplant in first remission, the advantage for TBF in terms of relapse was more evident (HR 0.4, P = .02), leading to a trend for better LFS in favor of TBF (HR 0.7, P = .10), while OS did not differ between the two cohorts. In conclusion, TBF represents a valid myeloablative conditioning regimen providing significantly lower relapse and similar survival when compared with BuCy. Patients in first remission appear to gain the most from this protocol, as in this subgroup a tendency for better LFS was observed when compared with BuCy.

来源:Am J Hematol,查看原文。版权归原作者所有。

引用

  1. Saraceni F, Beohou E, Labopin M, et al. Thiotepa, busulfan and fludarabine compared to busulfan and cyclophosphamide as conditioning regimen for allogeneic stem cell transplant from matched siblings and unrelated donors for acute myeloid leukemia. Am J Hematol. 2018. PMID: 30033639. doi:10.1002/ajh.25225

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。